DIRECT- ACTING ANTI- HEPATITIS C AGENTS AND THE RISK OF HEPATOCELLULAR CARCINOMA DEVELOPMENT VS THE OLD AGENTS: DOES THE OLD STILL THE GOLD?
Direct acting anti-viral (DAA) are the newest medications used for treatment of Chronic hepatitis C (CHC). DAA agents were approved by the American Food and Drug Administration (FDA) in 2014 as a novel treatment for CHC. Commonly used DAA regimens include: Sofosbuvir plus Semiprevir or Ledipasvir for hepatitis C virus (HCV) genotype 1, and Sofosbuvir plus Velpatasvir for all HCV genotypes.[Full Text Article]